Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) Stock Competitors & Peer Comparison

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, RPRX has a market cap of 25.9B. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while RPRX trades at $58.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas RPRX's P/E ratio is 11.13. In terms of profitability, CUVL's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CUVL is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check RPRX's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while CORT trades at $113.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas CORT's P/E ratio is 325.03. In terms of profitability, CUVL's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, CUVL is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CORT's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas WBA's P/E ratio is -1.64. In terms of profitability, CUVL's ROE is N/A, compared to WBA's ROE of -0.57%. Regarding short-term risk, CUVL is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check WBA's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while KNSA trades at $78.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas KNSA's P/E ratio is 80.55. In terms of profitability, CUVL's ROE is N/A, compared to KNSA's ROE of +0.14%. Regarding short-term risk, CUVL is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check KNSA's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, LQDA has a market cap of 5.9B. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while LQDA trades at $66.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas LQDA's P/E ratio is 48.49. In terms of profitability, CUVL's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, CUVL is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check LQDA's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, PBH has a market cap of 2.2B. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while PBH trades at $46.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas PBH's P/E ratio is 10.59. In terms of profitability, CUVL's ROE is N/A, compared to PBH's ROE of +0.09%. Regarding short-term risk, CUVL is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check PBH's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas HROWL's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, CUVL is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HROWL's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas HROWM's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, CUVL is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HROWM's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, LTGO has a market cap of 1.3B. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while LTGO trades at $21.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas LTGO's P/E ratio is -11.41. In terms of profitability, CUVL's ROE is N/A, compared to LTGO's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check LTGO's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, HELP has a market cap of 846.7M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while HELP trades at $13.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas HELP's P/E ratio is -3.28. In terms of profitability, CUVL's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, CUVL is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check HELP's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while SVA trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas SVA's P/E ratio is -5.68. In terms of profitability, CUVL's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, CUVL is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SVA's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, ETRA has a market cap of 295.3M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while ETRA trades at $13.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas ETRA's P/E ratio is -5.25. In terms of profitability, CUVL's ROE is N/A, compared to ETRA's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ETRA's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, CELG-RI has a market cap of 254.5M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while CELG-RI trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to CELG-RI's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CELG-RI's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, HITI has a market cap of 231.1M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while HITI trades at $2.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas HITI's P/E ratio is -9.71. In terms of profitability, CUVL's ROE is N/A, compared to HITI's ROE of -0.36%. Regarding short-term risk, CUVL is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HITI's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, CTOR has a market cap of 97.2M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while CTOR trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas CTOR's P/E ratio is -2.22. In terms of profitability, CUVL's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, CUVL is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CTOR's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CUVL's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, CUVL is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ATLN's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, SDEV has a market cap of 49.1M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while SDEV trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas SDEV's P/E ratio is -0.17. In terms of profitability, CUVL's ROE is N/A, compared to SDEV's ROE of +7.90%. Regarding short-term risk, CUVL is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SDEV's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas RAD's P/E ratio is -0.05. In terms of profitability, CUVL's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, CUVL is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check RAD's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CUVL's ROE is N/A, compared to GLTO's ROE of -0.83%. Regarding short-term risk, CUVL is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check GLTO's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, NSRX has a market cap of 29.6M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while NSRX trades at $3.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas NSRX's P/E ratio is -4.78. In terms of profitability, CUVL's ROE is N/A, compared to NSRX's ROE of -1.59%. Regarding short-term risk, CUVL is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check NSRX's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, SCYX has a market cap of 27.7M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while SCYX trades at $4.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas SCYX's P/E ratio is -1.29. In terms of profitability, CUVL's ROE is N/A, compared to SCYX's ROE of -0.21%. Regarding short-term risk, CUVL is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SCYX's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, COSM has a market cap of 18.4M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while COSM trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas COSM's P/E ratio is -0.46. In terms of profitability, CUVL's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, CUVL is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check COSM's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, BFRI has a market cap of 14.9M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while BFRI trades at $1.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas BFRI's P/E ratio is -2.11. In terms of profitability, CUVL's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, CUVL is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BFRI's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, CNSY has a market cap of 13.1M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while CNSY trades at $1.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas CNSY's P/E ratio is -0.45. In terms of profitability, CUVL's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, CUVL is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CNSY's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, SCNX has a market cap of 12.4M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while SCNX trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas SCNX's P/E ratio is -0.15. In terms of profitability, CUVL's ROE is N/A, compared to SCNX's ROE of -0.54%. Regarding short-term risk, CUVL is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SCNX's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, BFRIW has a market cap of 11.6M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while BFRIW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, CUVL's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, CUVL is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check BFRIW's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CUVL's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CUVL is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CJJD's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas SSY's P/E ratio is -2.86. In terms of profitability, CUVL's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, CUVL is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SSY's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while POM trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas POM's P/E ratio is -0.13. In terms of profitability, CUVL's ROE is N/A, compared to POM's ROE of +0.16%. Regarding short-term risk, CUVL is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check POM's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, BGMS has a market cap of 5.3M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while BGMS trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas BGMS's P/E ratio is -0.27. In terms of profitability, CUVL's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, CUVL is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BGMS's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, EOCN has a market cap of 3.6M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while EOCN trades at $3.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas EOCN's P/E ratio is -0.25. In terms of profitability, CUVL's ROE is N/A, compared to EOCN's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check EOCN's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, PAVS has a market cap of 3.5M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while PAVS trades at $4.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas PAVS's P/E ratio is -0.05. In terms of profitability, CUVL's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, CUVL is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check PAVS's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CUVL's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CUVL is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check MDVL's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, CUVL is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ATNFW's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CUVL's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, CUVL is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BGMSP's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CUVL's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CUVL is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check AZNH's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CUVL's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CUVL is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check LFLYW's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, PRPH has a market cap of 148.9K. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while PRPH trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas PRPH's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, CUVL is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check PRPH's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, CPD has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas CPD's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, CUVL is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check CPD's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, POZN has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas POZN's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, CUVL is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check POZN's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CUVL's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CUVL is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SHPG's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, OREX has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas OREX's P/E ratio is -0.14. In terms of profitability, CUVL's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, CUVL is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check OREX's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CUVL's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CUVL is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check IPXL's competition here

Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CUVL stands at 293.5M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.80 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CUVL currently has a P/E ratio of 12.56, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CUVL's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CUVL is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check ESRX's competition here